Genmab — Juni 2018

[E_L]

• Admits Glaxo has very good BCMA drug, SC Dara very close. Glaxo eye toxicity problems. Potential for Dara Glaxo combi

[E_L]

• Repeated that chair time / long infusion time is still an issue in the US and expects a lot from SC (“massive impact”)

[E_L]

• Also that SC seems to show better effect as IV so far and much better tolerated. Filing 2019. Janssen wants to file together to get a broad label approval for SC.

[E_L]

• 1 more TV study to launch in H2 in ‘another’ solid cancer. Which one?

[Sukkeralf]

Hi EI - regarding "- Admits Glaxo has very good BCMA drug, SC Dara very close. Glaxo eye toxicity problems. Potential for Dara Glaxo combi" i remember it as the GSk patients have been through more lines of therapi (more sick)

[Sukkeralf]

and the same goes when comparing sc mono vs Iv mono - IV patients more sick

[Sukkeralf]

For me sc dosing is still mostly about convenience and longer patent life and even maybe higher price - but hopefully we will see better efficacy in the larger trials as well

[E_L]

yes, i guess we need more trial data on that. Jan seemed to think for SC it could have something to do with dosing , the way he spoke about it , it feels like he believes SC could indeed be better. Lets hope so

[GeorgeBest]

Lidt statistik til sammenligning: Bugspytkirtelkræft 48000 nye tilfælde per år i USA. MM 30000 nye tilfælde per år

[E_L]

o really? thought it was smaller. just imagine what would happen if that works…

[Bulder]

Sukker, i attakvis sclerose har man lange perioder i bedring. Og de sundhedsfaglige fraråder ikke graviditet: "Til kvinder, der planlægger graviditet inden for de nærmeste år, anbefales dog dimethylfumarat som førstevalg." i stedet for teriflunomid https://pro.medicin.dk/sygdomme/sygdom/318380

[Sukkeralf]

Så er aktien endelig i plus

[Sukkeralf]

Ok tak bulder

[Bulder]

Nice abstract E L. Should have known before listening myself

[E_L]

lol

[E_L]

http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=RssLanding&cat=news&id=2354368 Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

[lahn1]

Nice work EL!

[StockBull]

Good work EL - you got the share price up from -07 to +0.2 with all your inputs

[E_L]

hahaha

[bibob]

E L is the Best newsfinder. I agree with MJ to send some Heineken for free to him. E L. To where do we send .